Ozempic vs Mounjaro: What's the Actual Difference?
Ozempic and Mounjaro are brand names for semaglutide and tirzepatide. This guide explains the brand name landscape, what each contains, how they compare, and which is prescribed for what.
Ozempic and Mounjaro are brand names — not different drugs. Ozempic is a Novo Nordisk product containing Semaglutide. Mounjaro is an Eli Lilly product containing Tirzepatide. Understanding the active ingredients behind the brand names is the key to making sense of the comparison — because the differences between these two active compounds are real and meaningful.
The Complete Brand Name Decoder
| Brand Name | Active Ingredient | Indication | Maker | Max Dose |
|---|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes | Novo Nordisk | 2 mg/week |
| Wegovy | Semaglutide | Obesity / weight loss | Novo Nordisk | 2.4 mg/week |
| Rybelsus | Semaglutide (oral) | Type 2 diabetes | Novo Nordisk | 14 mg/day oral |
| Mounjaro | Tirzepatide | Type 2 diabetes | Eli Lilly | 15 mg/week |
| Zepbound | Tirzepatide | Obesity / weight loss | Eli Lilly | 15 mg/week |
The Real Comparison: Semaglutide vs. Tirzepatide
| Factor | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro/Zepbound) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP receptor agonist (dual) |
| Mean weight loss | ~15% body weight (STEP trials) | 15–23% body weight (SURMOUNT trials) |
| Half-life | ~7 days | ~5 days |
| Evidence Grade | A+ | A+ |
| FDA approval year | 2017 (T2D); 2021 (obesity) | 2022 (T2D); 2023 (obesity) |
| Cardiovascular outcomes | SELECT trial: 20% CV risk reduction | SURPASS-CVOT: ongoing |
| Post-market experience | 7+ years (Ozempic) | 3+ years (Mounjaro) |
| GI side effects | Common during titration | Similar; may be marginally less |
Which Should You Use?
For most people starting GLP-1 therapy, semaglutide (Ozempic or Wegovy) remains the first-choice recommendation — it has 7+ years of post-market safety data, completed cardiovascular outcomes trials, and established prescribing experience among physicians. The 15% average weight loss it produces is meaningful for the vast majority of patients.
Tirzepatide (Mounjaro or Zepbound) is the better choice for those who need more than semaglutide's typical weight loss, have significant insulin resistance, or are already at maximum semaglutide dose without reaching their goal. Its dual GIP + GLP-1 mechanism produces consistently greater fat loss — but with a shorter post-market track record.
Frequently Asked Questions
Is Ozempic the same as Wegovy?
Same active ingredient (semaglutide), but different formulations approved for different indications. Ozempic is approved for type 2 diabetes management at doses up to 2 mg/week. Wegovy is approved for obesity treatment at the higher dose of 2.4 mg/week. Some doctors prescribe Ozempic off-label for weight loss; Wegovy is the on-label product for obesity. Rybelsus is oral semaglutide for T2D.
Is Mounjaro the same as Zepbound?
Yes — same active ingredient (tirzepatide), different labels. Mounjaro is approved for type 2 diabetes. Zepbound is the obesity label. Eli Lilly got the T2D approval first (2022) and then the obesity label (2023). The pharmacology is identical; the difference is the FDA-approved indication and packaging.
Can I switch between these drugs?
Yes, with physician supervision. Both GLP-1 receptor agonists have overlapping mechanisms, so switching from Ozempic/Wegovy (semaglutide) to Mounjaro/Zepbound (tirzepatide) is done by stopping semaglutide and starting tirzepatide at its lowest titration dose. Direct head-to-head switching protocols exist but always require medical oversight given the class-effect contraindications that apply to both.
Why does Mounjaro cost more than Ozempic?
Both are expensive branded products without a generic. Pricing varies by insurance, pharmacy benefit manager, country, and whether a manufacturer coupon applies. As of 2024–2025, the list prices for both are broadly similar in the US — monthly costs without insurance range from $900–$1,200 for brand-name versions. Compounded versions from licensed pharmacies may be available at lower cost during shortage periods, but quality and regulatory status vary.
Do these medications cause muscle loss?
Yes — all GLP-1 agonist-driven weight loss involves some lean mass reduction. Trial data shows roughly 60–70% of the weight lost is fat and 30–40% is lean mass without deliberate resistance training. Adding progressive resistance training during treatment significantly improves the fat-to-lean ratio. Adequate protein intake (0.8–1 g per lb of target body weight) also helps preserve muscle during caloric deficit.
GLP-1 Questions?
Join Hacksmith's Peptalk for Ozempic vs Mounjaro discussions, titration experiences, and side effect management from the community.
Join the Community →All FDA-approved forms require a prescription. Consult a qualified healthcare provider. Dosing figures are from clinical trial data — not prescriptions.